Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort
Rheumatology International · 2025
DOI: 10.1007/s00296-025-05941-0 ↗At a glance
Journal article in Rheumatology International, 2025. Written by Yuki Imai and 2 co-authors. Institution: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan. Major MEDLINE topics: Polymyalgia Rheumatica, Antibodies, Monoclonal, Humanized, Glucocorticoids, Immunosuppressive Agents. 42 references.
Abstract (original language)
Není k dispozici žádný abstrakt.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan. ykaneko.z6@keio.jp.
Cite
APA
Imai, Y., Takanashi, S., & Kaneko, Y. (2025). Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort. Rheumatology International. https://doi.org/10.1007/s00296-025-05941-0
Vancouver
Imai Y, Takanashi S, Kaneko Y. Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort. Rheumatology International. 2025. doi:10.1007/s00296-025-05941-0
BibTeX
@article{Imai2025,
author = {Imai, Yuki and Takanashi, Satoshi and Kaneko, Yuko},
title = {Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort},
journal = {Rheumatology International},
year = {2025},
doi = {10.1007/s00296-025-05941-0}
}
EUVIMED